Similar articles

• Temsirolimus (Torisel) for advanced renal cell carcinoma.

  [No authors listed] [No authors listed] Med Lett Drugs Ther. 2007 Dec 17;49(1276):103-4. Med Lett Drugs Ther. 2007. PMID: 18084154 No abstract available.
• Temsirolimus, an mTOR inhibitor for treatment of patients with advanced renal cell carcinoma.

  Malizzia LJ, Hsu A. Malizzia LJ, et al. Clin J Oncol Nurs. 2008 Aug;12(4):639-46. doi: 10.1188/08.CJON.639-646. Clin J Oncol Nurs. 2008. PMID: 18676330 Review.
• Prolonged response to temsirolimus in a pre-treated patient with metastatic renal cell carcinoma and poor performance status.

  Jafri M, Douis H, Porfiri E. Jafri M, et al. Clin Oncol (R Coll Radiol). 2008 Oct;20(8):657-8. doi: 10.1016/j.clon.2008.06.002. Epub 2008 Jul 21. Clin Oncol (R Coll Radiol). 2008. PMID: 18644704 No abstract available.
• Mechanisms of Disease: survival benefit of temsirolimus validates a role for mTOR in the management of advanced RCC.

  Figlin RA. Figlin RA. Nat Clin Pract Oncol. 2008 Oct;5(10):601-9. doi: 10.1038/ncponc1173. Epub 2008 Jul 8. Nat Clin Pract Oncol. 2008. PMID: 18607393 Review.
• Temsirolimus in renal cell carcinoma.

  Otto T, Eimer C, Gerullis H. Otto T, et al. Transplant Proc. 2008 Dec;40(10 Suppl):S36-9. doi: 10.1016/j.transproceed.2008.10.006. Transplant Proc. 2008. PMID: 19100905